Lv3
278 积分 2023-01-29 加入
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
2个月前
已完结
A first-in-class oral clinical candidate targeting MLLT1 and 3 degradation for the treatment of advanced AML and ALL including menin inhibitor resistant / refractory disease
5个月前
已关闭
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
5个月前
已完结
Betting on β-catenin inhibitors in oncology
6个月前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
6个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
6个月前
已完结
Regulatory, product development, resources, and financial challenges associated with creating and commercializing combination products
10个月前
已关闭
Moving toward Meaningful Standards for Preclinical Performance Testing of Medical Devices and Combination Products with Antimicrobial Effects
10个月前
已完结
Moving toward Meaningful Standards for Preclinical Performance Testing of Medical Devices and Combination Products with Antimicrobial Effects
10个月前
已关闭
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
11个月前
已完结
皖公网安备34019202002308
